Seikagaku Corp. | Cash Flow

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
5,949
4,008
3,500
2,477
5,327
2,859
Depreciation, Depletion & Amortization
1,767
2,610
3,191
2,920
2,926
2,902
Other Funds
2
2
-
-
-
1,990
Funds from Operations
5,749
4,480
5,806
4,416
7,465
3,771
Changes in Working Capital
657
348
211
469
2,119
650
Net Operating Cash Flow
6,406
4,132
5,595
4,885
5,346
3,121
Capital Expenditures
8,065
1,518
2,440
1,086
1,371
Sale of Fixed Assets & Businesses
-
-
154
1
-
Purchase/Sale of Investments
4,767
5,237
1,169
2,451
2,694
Net Investing Cash Flow
3,162
3,304
3,416
3,502
4,066
Cash Dividends Paid - Total
1,448
1,476
1,476
1,474
1,754
Issuance/Reduction of Debt, Net
140
959
471
473
464
Net Financing Cash Flow
1,310
519
1,947
2,282
2,221
Net Change in Cash
2,371
564
147
1,033
948
Free Cash Flow
1,546
2,650
3,347
4,068
4,246
Other Sources
136
4,293
39
34
-
Change in Capital Stock
-
-
-
333
-
Exchange Rate Effect
437
255
85
134
7
Other Uses
-
842
-
-
-

About Seikagaku

View Profile
Address
Marunouchi Center Building, 10/F
Tokyo Tokyo 100
Japan
Employees -
Website http://www.seikagaku.co.jp
Updated 07/08/2019
Seikagaku Corp. engages in the manufacture and sale of pharmaceuticals and medical devices specifically related to glycoconjugates. It operates through the following segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL). The Pharmaceuticals segment develops and supplies intra-articular injections for improving joint functions, cross-linked hyaluronate hydrogel for knee osteoarthritis, opthalmic surgical aids, and surgical aids for endoscopic mucosal resection.